You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 23, 2025

Patent: 10,011,635


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,011,635
Title:Cyclic peptide conjugates and methods of use
Abstract: The present invention concerns cyclic compounds, compositions comprising the cyclic compounds, linkers, a method of preparing a carrying agent:cyclic compound adduct, a method for treating disorders such as proliferation disorders (e.g., malignancies), bone deficiency diseases, and autoimmune diseases, and a method for suppressing the growth of, or inducing apoptosis in, cells (e.g., malignant cells).
Inventor(s): Hazlehurst; Lori (Morgantown, WV), Rader; Christoph (Jupiter, FL), Li; Xiuling (Jupiter, FL), McLaughlin; Mark (Tampa, FL)
Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (Tampa, FL) UNIVERSITY OF SOUTH FLORIDA (Tampa, FL) MODULATION THERAPEUTICS (Tampa, FL) THE SCRIPPS RESEARCH INSTITUTE (La Jolla, CA)
Application Number:15/024,928
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive Analysis of United States Patent 10,011,635: Navigating the Complexities of Patent Claims and Landscape

Introduction

When analyzing a patent, particularly one like United States Patent 10,011,635, it is crucial to delve into the intricacies of the claims, the patent landscape, and the legal and procedural aspects that govern patent law. This analysis will provide a detailed overview of the key components involved in evaluating a patent, using U.S. Patent 10,011,635 as a case study.

Understanding the Patent Claims

Claim Structure and Scope

Patent claims are the heart of any patent application, defining the scope of the invention and what is protected. For U.S. Patent 10,011,635, each claim must be carefully examined to understand what is being claimed. This involves identifying the independent and dependent claims, as well as any limitations or specific embodiments described within the claims[3].

Anticipation and Novelty

A critical aspect of patent claims is ensuring they are novel and non-obvious. Under 35 U.S.C. § 102, a claimed invention can be rejected if it is anticipated by prior art. This means every element of the claim must be found in a single prior art reference, either expressly or inherently described[3].

Example: Anticipation Analysis

For instance, if a prior art reference discloses a range of compositions that overlaps with the claimed range, it must do so with "sufficient specificity" to anticipate the claim. If the prior art does not meet this criterion, the claim may still be valid despite some overlap[3].

Patent Landscape and Prior Art

Conducting a Patentability Search

To assess the validity of a patent, a thorough patentability search is essential. This involves identifying references that disclose similar inventions through a comprehensive search of global patent publications and non-patent literature. Such searches help determine if the claims should be revised and inform decisions on whether to proceed with the patent filing[5].

Importance of Objective Review

An objective review of the patent application is crucial to avoid future problems. Tools like LexisNexis PatentOptimizer® can automate the review process, helping to identify clerical errors, ambiguous drafting language, and other critical issues that might otherwise be overlooked[2].

Obviousness-Type Double Patenting (ODP)

Definition and Implications

ODP is a doctrine that prevents an inventor from securing a second, later-expiring patent for an invention covered by a patent that was filed at the same time but has a different patent term due to a grant of Patent Term Adjustment (PTA). This is particularly relevant in cases where multiple patents in the same family have different expiration dates due to PTA grants[1].

Case Study: In re Cellect

The case of In re Cellect highlights the complexities of ODP. Here, multiple patents in the same family were subject to ODP analysis, and the court determined that the expiration dates of the patents, including any PTA, were critical in assessing ODP. The decision emphasized that ODP prevents an inventor from extending the term of a patent past the date of a terminal disclaimer[1].

Use of AI Tools in Patent Drafting

USPTO Guidance

The USPTO has issued guidance on the use of AI tools in patent drafting, emphasizing the need for thorough review of documents generated or assisted by AI. Practitioners must ensure that all statements in the paper are true and based on information believed to be true, as AI tools can omit, misstate, or "hallucinate" information[4].

Ensuring Accuracy and Compliance

When AI tools are used to draft or edit patent applications, it is crucial to verify the technical accuracy of the documents. This includes ensuring that any contributions made by AI do not introduce inaccurate statements or omit material information relevant to patentability[4].

Terminal Disclaimers and Patent Term Adjustments

Impact on Patent Term

Terminal disclaimers and Patent Term Adjustments (PTAs) can significantly affect the term of a patent. A terminal disclaimer is used to overcome ODP rejections by disclaiming the term of a later-expiring patent. PTAs, on the other hand, extend the term of a patent due to delays in the prosecution process. However, as seen in In re Cellect, PTAs do not extend the term past the date of a terminal disclaimer[1].

Legal and Procedural Aspects

Jurisdiction and Appeal Process

In cases where patent claims are rejected, the appeal process involves jurisdiction under 28 U.S.C. § 1295(a)(4)(A). The Federal Circuit has jurisdiction over appeals from the Patent Trial and Appeal Board (PTAB), allowing for a thorough review of the Board's decisions[1].

Section 112 Rejections

Patent applications can also face rejections under Section 112 of the U.S. patent laws, which deal with the written description, enablement, and definiteness requirements. An objective review using tools like PatentOptimizer® can help avoid these rejections by identifying ambiguities and ensuring compliance with these requirements[2].

Key Takeaways

  • Thorough Claim Analysis: Each claim must be meticulously examined to ensure novelty and non-obviousness.
  • Objective Review: Automated tools can enhance the review process, reducing the risk of errors and omissions.
  • ODP Considerations: Understanding ODP is crucial, especially in cases involving multiple patents with different expiration dates.
  • AI Tool Compliance: Ensure thorough review of AI-generated documents to maintain accuracy and compliance with USPTO guidelines.
  • Terminal Disclaimers and PTAs: These can significantly impact the term of a patent and must be carefully managed.

FAQs

Q: What is the importance of an objective review in patent drafting?

An objective review is crucial to avoid future problems such as procedural objections, Section 112 rejections, and post-grant challenges. It helps in producing stronger, more defensible patents by identifying clerical errors and ambiguities early in the process[2].

Q: How does ODP affect patent term?

ODP prevents an inventor from securing a second, later-expiring patent for an invention covered by a patent that was filed at the same time but has a different patent term due to a grant of PTA. This ensures that the term of a patent is not extended past the date of a terminal disclaimer[1].

Q: What are the risks associated with using AI tools in patent drafting?

AI tools can omit, misstate, or "hallucinate" information. Therefore, it is essential to thoroughly review documents generated or assisted by AI to ensure accuracy and compliance with USPTO guidelines[4].

Q: How can a patentability search help in the patent process?

A patentability search helps identify references that disclose similar inventions, allowing for informed decisions on whether to proceed with the patent filing and whether the claims should be revised[5].

Q: What is the role of terminal disclaimers in overcoming ODP rejections?

Terminal disclaimers are used to overcome ODP rejections by disclaiming the term of a later-expiring patent, ensuring that the term of the patent does not extend past the date of the terminal disclaimer[1].

Sources:

  1. In re Cellect, United States Court of Appeals for the Federal Circuit, 2023.
  2. Patent Analysis Tools for Objective Application Review, LexisNexis IP, 2021.
  3. Anticipation — Application of 35 U.S.C. 102, USPTO, 2023.
  4. U.S. Patent Office Issues Additional Guidance on Use of AI Tools, BIPC, 2024.
  5. Patent Search Services, Clarivate, 2023.

More… ↓

⤷  Try for Free

Details for Patent 10,011,635

ApplicantTradenameBiologic IngredientDosage FormBLAApproval DatePatent No.Expiredate
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 January 15, 1974 ⤷  Try for Free 2033-09-27
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 December 27, 1984 ⤷  Try for Free 2033-09-27
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 February 15, 1985 ⤷  Try for Free 2033-09-27
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 February 16, 1990 ⤷  Try for Free 2033-09-27
Bel-mar Laboratories, Inc. CHORIONIC GONADOTROPIN chorionic gonadotropin Injection 017054 March 26, 1974 ⤷  Try for Free 2033-09-27
Fresenius Kabi Usa, Llc CHORIONIC GONADOTROPIN chorionic gonadotropin For Injection 017067 March 05, 1973 ⤷  Try for Free 2033-09-27
>Applicant>Tradename>Biologic Ingredient>Dosage Form>BLA>Approval Date>Patent No.>Expiredate
Showing 1 to 6 of 6 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.